Predictors of response to neoadjuvant checkpoint inhibition with chemotherapy in triple-negative breast cancer (TNBC): A meta-analysis of randomized control trials (RCTs)

被引：0
|
作者：
Roy, A. M. [1 ]
Attwood, K. [2 ]
Gandhi, S. [1 ]
机构：
[1] Roswell Pk Comprehens Canc Ctr, Med Oncol Hematol, Buffalo, NY USA
[2] Roswell Pk Comprehens Canc Ctr, Biostat, Buffalo, NY USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.03.176
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
158P
引用
收藏
页码：S192 / S192
页数：1
相关论文
共 50 条
  • [41] Neoadjuvant therapy in triple-negative breast cancer: A systematic review and network meta-analysis
    Lin, Ying-Yi
    Gao, Hong-Fei
    Yang, Xin
    Zhu, Teng
    Zheng, Xing-xing
    Ji, Fei
    Zhang, Liu-Lu
    Yang, Ci-Qiu
    Yang, Mei
    Li, Jie-Qing
    Cheng, Min-Yi
    Wang, Kun
    BREAST, 2022, 66 : 126 - 135
  • [42] Platinum is essential in neoadjuvant treatment of triple-negative breast cancer: a network meta-analysis
    Junjie Li
    Li Chen
    Wei Tan
    Fang Qi
    Yang Zhang
    Zhonghua Wang
    Zhimin Shao
    Cancer Biology & Medicine, 2022, 19 (05) : 742 - 754
  • [43] Effective inhibition of metastasis in triple-negative breast cancer (TNBC) mouse model by combining immunogenic chemotherapy and immune checkpoint blockade
    Yuan, Xiangliang
    Xiao, Yi
    Liu, Xianghua
    Kuo, Wenling
    Li, Hongzhong
    Li, Ping
    Yagita, Hideo
    Yu, Dihua
    CANCER RESEARCH, 2018, 78 (13)
  • [44] Association of TNBC-DX scores with outcomes in triple-negative breast cancer (TNBC) treated with neoadjuvant pembrolizumab and chemotherapy: a correlative analysis from NeoPACT and NeoSTOP trials
    Sharma, Priyanka
    Stecklein, Shane R.
    Yoder, Rachel
    Staley, Joshua M.
    Salgado, Roberto
    Pare, Laia
    Conte, Benedetta
    Braso-Maristany, Fara
    O'Dea, Anne
    Nye, Lauren
    Elia, Manana
    Satelli, Deepti
    Crane, Gregory
    McKittrick, Richard
    Khan, Qamar
    Godwin, Andrew K.
    Prat, Aleix
    CANCER RESEARCH, 2023, 83 (05)
  • [45] Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
    Jung, Yoon Yang
    Hyun, Chang Lim
    Jin, Min-Sun
    Park, In Ae
    Chung, Yul Ri
    Shim, Bobae
    Lee, Kyu Ho
    Ryu, Han Suk
    JOURNAL OF BREAST CANCER, 2016, 19 (03) : 261 - 267
  • [46] The response to neoadjuvant chemotherapy and prognosis of triple-negative breast cancer patients.
    Nakano, E.
    Hojo, T.
    Masumura, K.
    Kikuyama, M.
    Akashi, S.
    Kinoshita, T.
    CANCER RESEARCH, 2009, 69 (02) : 337S - 337S
  • [47] Clinical and pathological response to neoadjuvant chemotherapy (NCT) in patients with triple negative breast cancer (TNBC)
    Krivorotko, P.
    Zhiltsova, E.
    Gigolaeva, L.
    Emelyanov, A.
    Pesotsky, R.
    Ereschenko, S.
    Levsghenko, V.
    Nikolaev, K.
    Komayachov, A.
    Ivanova, O.
    Tabagua, T.
    Zernov, K.
    Ivanov, V.
    Aseeva, Z.
    Bessonov, A.
    Semiglazov, V.
    BREAST, 2021, 56 : S52 - S52
  • [48] Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression
    Asano, Yuka
    Kashiwagi, Shinichiro
    Goto, Wataru
    Takada, Koji
    Takahashi, Katsuyuki
    Morisaki, Tamami
    Fujita, Hisakazu
    Takashima, Tsutomu
    Tomita, Shuhei
    Ohsawa, Masahiko
    Hirakawa, Kosei
    Ohira, Masaichi
    JOURNAL OF TRANSLATIONAL MEDICINE, 2018, 16
  • [49] Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression
    Yuka Asano
    Shinichiro Kashiwagi
    Wataru Goto
    Koji Takada
    Katsuyuki Takahashi
    Tamami Morisaki
    Hisakazu Fujita
    Tsutomu Takashima
    Shuhei Tomita
    Masahiko Ohsawa
    Kosei Hirakawa
    Masaichi Ohira
    Journal of Translational Medicine, 16
  • [50] A meta-analysis of the effect and safety of platinum-based neoadjuvant chemotherapy in treatment of resectable triple-negative breast cancer
    Feng, Wuna
    He, Yujing
    Xu, Jingsi
    Zhang, Hongya
    Si, Yuexiu
    Xu, Jiaxuan
    Li, Shengzhou
    ANTI-CANCER DRUGS, 2022, 33 (01) : E52 - E60
12345